Healthcare / BiotechnologyShanghai
$52.01
-1.34 (-2.51%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-34.1M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.4B
P/E
N/A
•EV/EBITDA
129.4x
↑ROE
-1.4%
↓Gross Margin
63.2%
↑Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-60.6%
FCF CAGR
—
FCF margin
-10.1%
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $339.0M · net income $-41.1M · FCF $-34.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $339.0M | $339.0M | $349.6M | $403.2M | $5.53B |
| Net Income | $-41.1M | $-41.1M | $-2.0M | $-373.8M | $1.83B |
| EBITDA | $32.9M | $32.9M | $70.6M | $-289.8M | $2.24B |
| EPS | -0.49 | -0.49 | -0.02 | -4.31 | 21.07 |
| Gross Margin | 63.2% | 63.2% | 62.3% | 63.9% | 60.6% |
| Operating Margin | -17.4% | -17.4% | -11.0% | -53.2% | 44.5% |
| Net Margin | -12.1% | -12.1% | -0.6% | -92.7% | 33.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.07 | 0.05 | 0.03 |
| Current Ratio | 3.33 | 3.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-34.1M | $-34.1M | $83.1M | $-224.5M | $1.61B |
| Returns | |||||
| ROE | -1.4% | -1.4% | -0.1% | -11.0% | 48.4% |
| Valuation | |||||
| P/E | — | — | — | — | 2.83 |
| EV/EBITDA | 129.40 | 129.40 | 51.29 | — | 1.56 |
| P/B | 1.49 | 1.49 | 1.29 | 0.95 | 1.37 |
| Growth & Yield | |||||
| Revenue Growth | -3.0% | -3.0% | -13.3% | -92.7% | — |
| EPS Growth | -2350.0% | -2350.0% | 99.5% | -120.5% | — |
| Dividend Yield | 6.4% | 6.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.49
Residual
+8.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.